Last reviewed · How we verify

NCT03551002

Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

Status unknown Last updated 5 September 2021
What this trial tests

trial in Hepatitis C in 450 participants. Status unknown.

Timeline
1 January 2018
Primary endpoint
31 December 2021
31 December 2021

Quick facts

Lead sponsorUniversity of California, San Diego
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment450
Start date1 January 2018
Primary completion31 December 2021
Estimated completion31 December 2021
Sites1 location across United States

Conditions studied

Sponsor

University of California, San Diego

Who can join

18 and older, any sex, with Hepatitis C or Hepatitis C, Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A retrospective and prospective study among people living with HIV (PLWH) that assesses hepatitis C (HCV) treatment uptake during periods before and after direct acting antivirals (DAA) introduction, and its impact on the HCV epidemic among PLWH.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

Other University of California, San Diego trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03551002.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing